EN DE
Watch ChengDa Pharmaceuticals Co. Ltd. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

ChengDa Pharmaceuticals Co. Ltd. (301201) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of ChengDa Pharmaceuticals Co. Ltd. stock ¥4.98, price ¥21.70, that is 77.1% below the price, quality 53 out of 100. Rating: strongly overvalued. Calculated from audited financials with 6 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare CN · ISIN CNE100005766

CP ChengDa Pharmaceuticals Co. Ltd. logo Some data Nov 14, 2026

ChengDa Pharmaceuticals Co. Ltd.

301201 · SHE

Far too expensive (fair value 77% below the price) and falling price, but solid company: meets 1 of 3 rules.

Get notified free when this changes
Low debt 
Quality 53/100 
0.9% dividend yield · Token dividend
Some data 
Profit last quarter 74% below a year ago. 
Fair value ¥4.98 · Strongly overvalued 
Falling price (downtrend) 
Weak Growth (revenue 5y +1.7 %/yr in CNY) 
Loss-making · -8.6% net margin (TTM) 
Negative free cash flow 
Trails peers (2/12) 
Narrow moat 19/100
Watch ChengDa Pharmaceuticals Co. Ltd. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

¥85.72 ¥14.84 Fair Value ¥4.98 Jan 2022 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 14, 2026.

How to read this chart

58‑month range ¥14.84 – ¥85.72 · fair‑value band ¥4.47 – ¥5.04 · the ¥21.70 price screens above the ¥4.98 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 14, 2026.

Follow ChengDa Pharmaceuticals Co. in your weekly email

Every Wednesday you see whether ChengDa Pharmaceuticals Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

ChengDa Pharmaceuticals Co., Ltd. engages in the research and development, production, and sale of pharmaceutical intermediates, chemical ingredients, and food and feed additives in China and internationally.

Show moreShow less

It offers process research and development, process optimization, quality and stability research, customized production and other services for pharmaceutical intermediates and APIs; and food and feed additives, such as L-carnitine and L-carnitine tartrate.

The company also provides bulk drug products, including urogenital, nervous system, blood and hematopoietic organs, muscular system, digestive tract and metabolism, antineoplastic and immunomodulators; and pharmaceutical intermediates comprising drug intermediates for blood and hematopoietic organs, drug intermediates in digestive tract and metabolism, and nervous system drug intermediates.

ChengDa Pharmaceuticals Co., Ltd. was founded in 1980 and is based in Jiaxing, China.

Stock analysis

ChengDa Pharmaceuticals Co. Ltd. (301201) currently trades at ¥21.70, while our model-based Fair Value estimate is ¥4.98, 77% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Asset-Based group reads highest at a median of ¥6.78 per share, and 0 of the 6 models we run sit above the ¥21.70 price.

Bear case: the Multiples group reads lowest at ¥1.25, and 6 of the 6 models stay below the price. Data coverage for this calculation is medium.

Scenario range: ¥4.47 (bear) to ¥5.04 (bull), the price of ¥21.70 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 53/100 (solid quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak: less than 2 % a year.

ChengDa Pharmaceuticals Co. Ltd. reported revenue of 406M CNY in FY2025 versus 416M CNY in FY2021, a compound −0.6%/yr. Reported net income was −11.9M CNY in FY2025.

Key figures

Market cap 3.4B CNY (≈ $505M) Small · P/S ratio 7.42 · EPS (TTM) ¥−0.2700 · Dividend yield 0.9% · Net margin −8.6% · Return on equity −2.0% · Return on assets (EBIT) 4.5% (5-year average) · Operating margin −7.7%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 19 out of 100 (medium confidence).

What moves the price

The share trades about 65% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −77%, 301201 screens richer than that median.

Fair Value models

The price assumes far more growth than our models allow for, so the models scatter widely (¥0.9000 to ¥7.59). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear ¥4.47 Fair Value ¥4.98 Bull ¥5.04
Price ¥21.70 · Downside -77.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
ROIC Compounder ¥4.92 ¥4.98 ¥5.04 72
EPV ¥4.92 ¥4.98 ¥5.04 71
EV/EBITDA ¥5.64 ¥7.59 ¥9.55 67
All 6 models by family
Earnings-Based
EPV ¥4.92 ¥4.98 ¥5.04 71
Multiples
EV/EBIT ¥0.8800 ¥1.25 ¥1.62 65
EV/EBITDA ¥5.64 ¥7.59 ¥9.55 67
EV/Revenue ¥0.5600 ¥0.9000 ¥1.24 53
Asset-Based
NCAV (Graham) ¥4.47 ¥6.78 ¥8.47 54
Economic Profit
ROIC Compounder ¥4.92 ¥4.98 ¥5.04 72

Open the full fair value analysis →

Quality Score breakdown

Overall quality 53/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 10
How much profit the company makes from its sales and capital
Quality Growth 76
Are margins and returns getting better?
Cashflow 13
Do the profits arrive as real cash?
Financial strength 87
Debt, balance sheet and risk of trouble
Investment 72
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 5
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 15/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
+22.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.7%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.5%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
27.9% (2020) → 3.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

301201 screens overvalued: fair value 77% below the price. Compare with Merck KGaA →

Compare ChengDa Pharmaceuticals Co. Ltd. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 604 stocks

Beats the industry median on 2/11 measures
Overall it trails its industry peers.
Valuation
Quality Score 53 · Below median
Fair Value upside −77.1% · Bottom 25%
Profitability
Return on assets −0.5% · Below median
Net margin (12 months) −8.6% · Bottom 25%
Operating margin (12 months) −7.7% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −2.4% · Below median
Dividend yield (12 months) 0.9% · Below median
Balance sheet
Debt / equity 0.02× · Below median

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 1.60× · Cheaper than median
P/S (12 months) 7.04× · Priciest 25%
EV/EBITDA 50.8× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 19
FUTURE (revenue growth)0 · sector 28
PAST (return on equity)0 · sector 26
HEALTH (low debt)99 · sector 96
DIVIDEND (yield)18 · sector 32

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $84.39 $113.53 +35% vs 301201
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥48.02 ¥53.04 +10% vs 301201
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,868 ₹1,983 +6% vs 301201
Haleon plc HLN $9.20 $8.47 −8% vs 301201
Merck KGaA MRK €149.70 €108.83 −27% vs 301201
Galderma Group GALD CHF 191.00 CHF 112.46 −41% vs 301201
Takeda Pharmaceutical Company TAK $21.59 $11.23 −48% vs 301201
Teva Pharmaceutical Industries Limited TEVA $42.57 $20.74 −51% vs 301201
Sandoz Group SDZ CHF 84.60 CHF 40.54 −52% vs 301201
Divi's Laboratories Limited DIVISLAB ₹11,080 ₹1,567 −86% vs 301201

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

ChengDa Pharmaceuticals Co. Ltd.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "ChengDa Pharmaceuticals Co. Ltd. Fair Value". https://www.fairvalue-calculator.com/stock/301201

Frequently asked questions

Is ChengDa Pharmaceuticals Co. Ltd. (301201) overvalued or undervalued?
As of Nov 14, 2026, our model estimates a fair value of ¥4.98 versus a price of ¥21.70, about 77% lower (overvalued).
What is the fair value of 301201?
Our model-based fair value for ChengDa Pharmaceuticals Co. Ltd. is ¥4.98 (as of Nov 14, 2026), built from audited fundamentals. The current price: ¥21.70.
What is the quality score of 301201?
ChengDa Pharmaceuticals Co. Ltd. has a Quality Score of 53/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for ChengDa Pharmaceuticals Co. Ltd. (301201)?
Our model-based price target is the fair value of ¥4.98 (as of Nov 14, 2026) from 6 valuation models. Cautious scenario ¥4.47, optimistic scenario ¥5.04. It is a calculation from audited fundamentals, not an analyst target.
What is the ChengDa Pharmaceuticals Co. Ltd. stock forecast for 2026?
Our models put fair value at ¥4.98, about 77% lower versus a price of ¥21.70 (overvalued). Cautious scenario ¥4.47, optimistic scenario ¥5.04. The calculation is refreshed regularly with new filings.
What is the revenue of ChengDa Pharmaceuticals Co. Ltd. (301201)?
ChengDa Pharmaceuticals Co. Ltd. reported trailing-twelve-month revenue of about 477M CNY (latest available figure, as of Nov 14, 2026).
Does ChengDa Pharmaceuticals Co. Ltd. pay a dividend?
ChengDa Pharmaceuticals Co. Ltd. currently shows a dividend yield of 0.92% relative to its recent price (as of Nov 14, 2026).
How much is the dividend of ChengDa Pharmaceuticals Co. Ltd. (301201) and when is the ex-dividend date?
ChengDa Pharmaceuticals Co. Ltd. pays a dividend of ¥0.2 per share a year, a dividend yield of 0.9%. The last ex-dividend date was Jul 15, 2026. A dividend has been paid every year since at least 2022. Our assessment: Token dividend. At a yield of 0.9% the dividend is symbolic. On paper it is not fully covered by earnings or free cash flow, but at this size that hardly matters: even scrapping it entirely would cost less than 0.9% a year, and coverage ratios on amounts this small swing with ordinary working-capital movements. Judge this company on its business, not on its dividend.
What is the intrinsic value of ChengDa Pharmaceuticals Co. Ltd. (301201)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For ChengDa Pharmaceuticals Co. Ltd. it is ¥4.98 per share (as of Nov 14, 2026), against a price of ¥21.70. It is the blended result of 6 valuation models in 4 families (Earnings-Based, Multiples, Asset-Based, Economic Profit).
Is ChengDa Pharmaceuticals Co. Ltd. stock overvalued or undervalued in 2026?
As of Nov 14, 2026, 301201 trades above its calculated fair value: price ¥21.70, fair value ¥4.98, a gap of about −77% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 301201?
No. The price is what the market pays today (¥21.70); the fair value is what the company's own numbers justify (¥4.98). For ChengDa Pharmaceuticals Co. Ltd. the two are ¥16.72 per share apart. That gap is exactly why we show both numbers side by side.
How much is ChengDa Pharmaceuticals Co. Ltd. worth?
The market values ChengDa Pharmaceuticals Co. Ltd. at about 3.4B CNY (market capitalisation, as of Nov 14, 2026). Per share that is ¥21.70; our models calculate a fair value of ¥4.98 per share.
What do the bullish and bearish scenarios say about 301201?
Our models span a range for ChengDa Pharmaceuticals Co. Ltd.: cautious scenario ¥4.47, base ¥4.98, optimistic ¥5.04 per share (as of Nov 14, 2026, price ¥21.70). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of ChengDa Pharmaceuticals Co. Ltd. (301201)?
Balance-sheet figures for ChengDa Pharmaceuticals Co. Ltd. (as of Nov 14, 2026): return on equity −2.0%, debt of 0.02 per unit of equity. They feed the Quality Score of 53/100, which measures business quality independently of the share price.
How far is 301201 from its 52-week high?
ChengDa Pharmaceuticals Co. Ltd. trades at ¥21.70, about 65% below its 52-week high of ¥62.41 and at the low of ¥21.70 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of ¥4.98 is for.
Which stocks are comparable to ChengDa Pharmaceuticals Co. Ltd.?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is ChengDa Pharmaceuticals Co. Ltd. stock attractive at the current price?
The data as of Nov 14, 2026: price ¥21.70, calculated fair value ¥4.98 (−77%), Quality Score 53/100, from 6 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 301201 calculated?
We run ChengDa Pharmaceuticals Co. Ltd. through 6 models from 4 families: Earnings-Based, Multiples, Asset-Based, Economic Profit. Every model gets the same audited fundamentals; the fair value of ¥4.98 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. ChengDa Pharmaceuticals Co. Ltd. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of ChengDa Pharmaceuticals Co. Ltd. (301201)?
The closing price on Nov 16, 2026 was ¥21.70. Our model-based fair value is ¥4.98, about 77% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with ChengDa Pharmaceuticals Co. Ltd. right now?
The price sits above even our optimistic bull case (¥5.04). The favourable scenario is already priced in. Solid but not exceptional quality (53/100) and above fair value, neither a clear bargain nor a standout compounder. The models converge in a tight band (¥4.47 to ¥5.04), unusually little disagreement for a valuation.

Key figures of ChengDa Pharmaceuticals Co. Ltd.

How large is the market capitalisation of ChengDa Pharmaceuticals Co. Ltd. (301201)?
The market capitalisation of ChengDa Pharmaceuticals Co. Ltd. is 3.4B CNY (≈ $505M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of ChengDa Pharmaceuticals Co. Ltd. (301201)?
The price-to-sales ratio of ChengDa Pharmaceuticals Co. Ltd. is 7.42 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of ChengDa Pharmaceuticals Co. Ltd. (301201)?
Earnings per share at ChengDa Pharmaceuticals Co. Ltd. are ¥−0.2700. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of ChengDa Pharmaceuticals Co. Ltd. (301201)?
The dividend yield of ChengDa Pharmaceuticals Co. Ltd. is 0.9%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of ChengDa Pharmaceuticals Co. Ltd. (301201)?
The net margin of ChengDa Pharmaceuticals Co. Ltd. is −8.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of ChengDa Pharmaceuticals Co. Ltd. (301201)?
The return on equity (ROE) of ChengDa Pharmaceuticals Co. Ltd. is −2.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of ChengDa Pharmaceuticals Co. Ltd. (301201)?
On an EBIT basis the return on assets of ChengDa Pharmaceuticals Co. Ltd. is 4.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of ChengDa Pharmaceuticals Co. Ltd. (301201)?
The operating margin of ChengDa Pharmaceuticals Co. Ltd. is −7.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at ChengDa Pharmaceuticals Co. Ltd. (301201)?
Revenue at ChengDa Pharmaceuticals Co. Ltd. is down 2.4% versus a year earlier (3y avg −0.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at ChengDa Pharmaceuticals Co. Ltd. (301201)?
Earnings per share at ChengDa Pharmaceuticals Co. Ltd. are down 74.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does ChengDa Pharmaceuticals Co. Ltd. (301201) generate?
The free cash flow of ChengDa Pharmaceuticals Co. Ltd. is −35.0M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does ChengDa Pharmaceuticals Co. Ltd. (301201) carry?
The net debt of ChengDa Pharmaceuticals Co. Ltd. is 35.6M CNY (fiscal year 2021). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch ChengDa Pharmaceuticals Co. Ltd. in the live analysis

One click puts ChengDa Pharmaceuticals Co. Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.